Quantcast

Latest Midbrain Stories

2010-10-19 11:26:00

SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online...

2010-07-22 01:20:58

Rui Costa, Principal Investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciência (Portugal), and Xin Jin, of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health (USA), describe in the latest issue of the journal Nature(*), that the activity of certain neurons in the brain can signal the initiation and termination of behavioural sequences we learn anew. Furthermore, they found that this brain activity is...

2010-04-28 06:00:00

SAN DIEGO, April 28 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up....

0ee18f812769481027f838650b28ac701
2010-04-07 08:06:54

In Germany alone, more than 300,000 people are afflicted by Parkinson's disease and the number is growing steadily. However, despite comprehensive research, scientists are still somewhat in the dark as to the molecular changes that trigger this illness. Scientists at the Max Planck Institute of Neurobiology in Martinsried, Germany, together with colleagues from Munich and Hamburg, have demonstrated using a new animal model that nerve cells do not begin to die to the extent found in...

2009-08-24 17:08:24

Parkinson's disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown. Recent research revealed that about ten per cent of cases are caused by defects in so-called Parkinson-associated genes. Furthermore, mitochondria, the cellular powerhouses, seem to play a major role. New results from researchers at the LMU Munich under the lead of associate professor Dr. Konstanze Winklhofer and Professor Christian...

2009-08-24 11:15:00

Parkinson's disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown. Recent research revealed that about ten per cent of cases are caused by defects in so-called Parkinson-associated genes. Furthermore, mitochondria, the cellular powerhouses, seem to play a major role. New results from researchers at the LMU Munich under the lead of associate professor Dr. Konstanze Winklhofer and Professor Christian...

2009-08-19 12:40:00

Dark cerebral matter fades in Parkinson's diseaseInvestigation of the human brain discloses a distinct dark discoloration of the substantia nigra and locus coeruleus within parts of the brainstem. This is due to the bluish to brown-black pigment neuromelanin, which is only present in the human brain and that of a few other mammals (primates, cows, horses, some breeds of sheep). Research into neuromelanin is particularly interesting because the substantia nigra of patients with PD fades in...

2009-08-05 08:00:00

SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease. The funding will enable Ceregene to collect and analyze more extensive data for up to 48 months from patients with advanced Parkinson's disease who were enrolled in the double-blind, controlled trial which ended in November 2008. As was...

2009-05-27 06:00:00

-- Longer term follow-up indicates modest efficacy in primary and related endpoints -- SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson's disease patients in order to restore the function and protect degenerating nigrostriatal neurons. The...

2009-04-07 10:54:33

University of Texas at San Antonio scientists say they've found the phasic firing of dopamine neurons is key to the brain's prediction of rewards. The researchers say their finding brings science a step closer to understanding the neurobiology that allows people to successfully learn motivated behaviors by associating environmental cues with rewarding outcomes. Assistant Professor Carlos Paladini and graduate student Collin Lobb collaborated with researchers at the University of Washington to...


Latest Midbrain Reference Libraries

Midbrain
2013-07-25 15:13:23

The midbrain, also known as the mesencephalon is the part of the brain most responsible for vision, motor control, arousal, temperature regulation, alertness and hearing. Formation and Orientation The midbrain is found under the cerebral cortex and above the hindbrain. The mesencephalon is not divided into any other portions of the brain unlike the other two vesicles that stem from the neural tube. There are four separate lobes on the side of the cerebral aqueduct within the...

More Articles (1 articles) »
Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related